January 16, 2007 – BioCryst started a pivotal tiral of its lead oncology drug, Fodosine; Advanced Cell Technology received a $200,000 NIH grant to work on stem cells; DOV Pharma out-licensed the world-wide rights for Bicifadine; Novovax improved its virus-like particle vaccine for HIV/AIDS; BioMarin reported positive data on Phenoptin for PKU; Nabi began a Phase II trial for Civacir in hepatitis C; Dendreon received priority review for cancer vaccine Provenge; Neurobiological Technologies received its final $4 million installment payment for Xerecept; Hollis-Eden reported positive preclinical data on an insuline sensitizer; Lilly completed enrollment in a trial that pits prasugrel against Plavix; the FDA accepted a new drug application for a Tercica drug for acromegaly; Merck Serono completed enrollment in a Phase III trial of an oral form of cladribine for multiple sclerosis; Watson Pharma reported positive results from two Phase III trials of silodosin; Genizon out-licensed to Pfizer the diagnostic rights for use of three genetic discoveries; and Hana Biosciences was given orphan drug designation for leukemia drug Mariqibo. The Centient Biotech 200™ rose 17 points to end a 4095, a gain of .42%. More details...
